Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?

被引：0
|
作者：
Arthur Kavanaugh
机构：
[1] Allergy,Professor of Medicine and the Director of the Center for Innovative Therapy in the Division of Rheumatology
[2] and Immunology at the University of California San Diego,undefined
来源：
Nature Clinical Practice Rheumatology | 2006年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tumor necrosis factor (TNF) inhibitors have proven highly effective in improving the signs and symptoms of rheumatoid arthritis, in inhibiting the progression of joint damage, and improving patients' quality of life. This Viewpoint will discuss the major concern relating to the actual use of TNF inhibitors in the clinic: their relatively high acquisition costs.
引用
收藏
页码：346 / 347
页数：1
相关论文
共 50 条
  • [41] Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
    Mewar, Devesh
    Wilson, Anthony G.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (04) : 785 - 791
  • [42] Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease
    Moghadam, Marjan Ghiti
    ten Klooster, Peter M.
    Vonkeman, Harald E.
    Kneepkens, Eva L.
    Klaasen, Ruth
    Stolk, Jan N.
    Tchetverikov, Ilja
    Vreugdenhil, Simone A.
    van Woerkom, Jan M.
    Goekoop-Ruiterman, Yvonne P. M.
    Landewe, Robert B. M.
    van Riel, Piet L. C. M.
    van de Laar, Mart A. F. J.
    Jansen, Tim L.
    ARTHRITIS CARE & RESEARCH, 2018, 70 (04) : 516 - 524
  • [43] Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era - Observations from Brazil
    Pinheiro, GDC
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2005, 11 (06) : 344 - 346
  • [44] Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
    Desai, Rishi J.
    Rao, Jaya K.
    Hansen, Richard A.
    Fang, Gang
    Maciejewski, Matthew L.
    Farley, Joel F.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (11): : 1110 - 1120
  • [45] Ischemic Colitis During Treatment with Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis
    Salk, Allison
    Stobaugh, Derrick
    Deepak, Parakkal
    Ehrenpreis, Eli
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S208 - S208
  • [46] Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
    Cannon, Grant W.
    DuVall, Scott L.
    Haroldsen, Candace L.
    Caplan, Liron
    Curtis, Jeffrey R.
    Michaud, Kaleb
    Mikuls, Ted R.
    Reimold, Andreas
    Collier, David H.
    Harrison, David J.
    Joseph, George J.
    Sauer, Brian C.
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (10) : 1935 - 1943
  • [47] Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
    Kim, Seoyoung C.
    Solomon, Daniel H.
    Rogers, James R.
    Gale, Sara
    Klearman, Micki
    Sarsour, Khaled
    Schneeweiss, Sebastian
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [48] The kynurenine pathway in patients with rheumatoid arthritis during tumor necrosis factor α inhibitors treatment
    Witoszynska-Sobkowiak, Joanna
    Sikorska, Dorota
    Niklas, Karolina
    Zychowska, Iwona
    Rutkowski, Rafal
    Samborski, Wlodzimierz
    REUMATOLOGIA, 2024, 62 (04): : 220 - 225
  • [49] Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis
    D'Arcy, Monica E.
    Beachler, Daniel C.
    Pfeiffer, Ruth M.
    Curtis, Jeffrey R.
    Mariette, Xavier
    Seror, Raphaele
    Mahale, Parag
    Rivera, Donna R.
    Yanik, Elizabeth L.
    Engels, Eric A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2021, 30 (11) : 2059 - 2067
  • [50] LABORATORY SAFETY OF ADALIMUMAB AND OTHER TUMOR NECROSIS FACTOR INHIBITORS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
    Pappas, D. A.
    Shaw, J. W.
    Chang, H.
    Cifaldi, M. A.
    Reed, G. W.
    Garg, V.
    Lacerda, A. P.
    Mozaffarian, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 931 - 931
12345